Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.81 |
| ▸ | SQLE | Q14534 | 8/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.71 |
| ▸ | ICMT | O60725 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295739 | 1.00 | KMT2A (0.81) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL30234223 | 1.00 | KMT2A (0.81) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL295738 | 1.00 | KMT2A (0.81) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL3099745 | 1.00 | KMT2A (0.81) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL29072183 | 0.90 | KMT2A (0.62) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL31354817 | 0.90 | KMT2A (0.62) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL23802597 | 0.90 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Squalene SCHEMBL8819997 | 0.90 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Squalene SCHEMBL890053 | 0.90 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL8013144 | 0.90 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3877519-B1 | BIOSYNTHESIS OF MOGROSIDES | GINKGO BIOWORKS INC (US) | 2026-03-11 | — | — | EP | claimed |
| CN-115887450-A | Synthesis of squalene temozolomide and preparation and application of self-assembled nanoparticles thereof | 杭州师范大学 | 2023-04-04 | — | — | CN | claimed |
| EP-4698673-A1 | STRAINS AND METHODS FOR THE PRODUCTION OF MOGROSIDES | DSM IP Assets B.V. (NL) | 2026-02-25 | — | — | EP | disclosed |
| US-12428662-B2 | Methods for making high intensity sweeteners | FIRMENICH INCORPORATED (US) | 2025-09-30 | — | — | US | disclosed |
| US-12338476-B2 | Methods for making high intensity sweeteners | FIRMENICH INCORPORATED (US) | 2025-06-24 | — | — | US | disclosed |
| US-12286661-B2 | Methods for making high intensity sweeteners | FIRMENICH INCORPORATED (US) | 2025-04-29 | — | — | US | disclosed |
| CN-112386504-B | Dispersible powder and cosmetic | 信越化学工业株式会社 | 2025-04-11 | — | — | CN | disclosed |
| CN-119709929-A | Method for preparing high intensity sweetener | 弗门尼舍公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-111108213-B | Method for preparing high intensity sweetener | 弗门尼舍公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118845537-A | Sheet-like cosmetic | 花王株式会社 | 2024-10-29 | — | — | CN | disclosed |
| WO-2024218244-A1 | STRAINS AND METHODS FOR THE PRODUCTION OF MOGROSIDES | DSM IP ASSETS B.V. (NL) | 2024-10-24 | — | — | WO | disclosed |
| EP-3095464-A1 | 5-ALA DERIVATIVES AND USE THEREOF | UNIVERSITE DE GENEVE (CH) | 2016-11-23 | — | — | EP | disclosed |
| CN-106083932-A | Novel preactivated oxazaphosphorin derivant, application and preparation method | 法国古士塔柏罗斯学院 | 2016-11-09 | — | — | CN | disclosed |
| CN-103328494-B | Novel pre-activated oxazaphosphorine derivatives, use and method for the production thereof | 法国古士塔柏罗斯学院 | 2016-08-10 | — | — | CN | disclosed |
| EP-2877577-A1 | EXTRACTS ISOLATED FROM ELECTROPORATED AMBHIBIAN OOCYTES AND USE THEREOF IN TREATING DISEASES AND DISORDERS | Bioquark, Inc. (US) | 2015-06-03 | — | — | EP | disclosed |
| CN-102245176-B | Fatty acids for use as a medicament | LIPID PHARMACEUTICALS EHF | 2015-05-27 | — | — | CN | disclosed |
| US-20140030244-A1 | EXTRACTS ISOLATED FROM ELECTROPORATED AMBHIBIAN OOCYTES AND USE THEREOF IN TREATING DISEASES AND DISORDERS | BIOQUARK, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2014018663-A1 | EXTRACTS ISOLATED FROM ELECTROPORATED AMBHIBIAN OOCYTES AND USE THEREOF IN TREATING DISEASES AND DISORDERS | BIOQUARK, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| CN-103328494-A | Novel pre-activated oxazaphosphorine derivatives, use and method for the production thereof | ROUSSY INST GUSTAVE | 2013-09-25 | — | — | CN | disclosed |
| CN-102245176-A | Fatty acids for use as a medicament | LIPID PHARMACEUTICALS EHF | 2011-11-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428662-B2 | Methods for making high intensity sweeteners | OXER1, MAN1B1, GMDS | KMT2A 2970/4885SQLE 522/4885MAPT 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.